Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Wolfram E. Samlowski; James Moon; J. Philip Kuebler; Craig R. Nichols; David R Gandara; Howard Ozer; Stephen K. Williamson; James N. Atkins; David E. Schuller; John F. Ensley

doi:10.1080/07357900701209061

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Wolfram E. Samlowski, James Moon, J. Philip Kuebler, Craig R. Nichols, David R Gandara, Howard Ozer, Stephen K. Williamson, James N. Atkins, David E. Schuller, John F. Ensley

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

Original language	English (US)
Pages (from-to)	182-188
Number of pages	7
Journal	Cancer Investigation
Volume	25
Issue number	3
DOIs	https://doi.org/10.1080/07357900701209061
State	Published - Apr 2007

Keywords

Carboplatin
Chemotherapy
Docetaxel
Head and neck cancer
Taxane

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1080/07357900701209061

Cite this

Samlowski, W. E., Moon, J., Kuebler, J. P., Nichols, C. R., Gandara, D. R., Ozer, H., Williamson, S. K., Atkins, J. N., Schuller, D. E., & Ensley, J. F. (2007). Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study. Cancer Investigation, 25(3), 182-188. https://doi.org/10.1080/07357900701209061

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. / Samlowski, Wolfram E.; Moon, James; Kuebler, J. Philip; Nichols, Craig R.; Gandara, David R; Ozer, Howard; Williamson, Stephen K.; Atkins, James N.; Schuller, David E.; Ensley, John F.

In: Cancer Investigation, Vol. 25, No. 3, 04.2007, p. 182-188.

Research output: Contribution to journal › Article › peer-review

Samlowski, WE, Moon, J, Kuebler, JP, Nichols, CR, Gandara, DR, Ozer, H, Williamson, SK, Atkins, JN, Schuller, DE & Ensley, JF 2007, 'Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study', Cancer Investigation, vol. 25, no. 3, pp. 182-188. https://doi.org/10.1080/07357900701209061

Samlowski, Wolfram E. ; Moon, James ; Kuebler, J. Philip ; Nichols, Craig R. ; Gandara, David R ; Ozer, Howard ; Williamson, Stephen K. ; Atkins, James N. ; Schuller, David E. ; Ensley, John F. / Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. In: Cancer Investigation. 2007 ; Vol. 25, No. 3. pp. 182-188.

@article{00d8ebd40bec41d3a5a2c82776896752,

title = "Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study",

abstract = "Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.",

keywords = "Carboplatin, Chemotherapy, Docetaxel, Head and neck cancer, Taxane",

author = "Samlowski, {Wolfram E.} and James Moon and Kuebler, {J. Philip} and Nichols, {Craig R.} and Gandara, {David R} and Howard Ozer and Williamson, {Stephen K.} and Atkins, {James N.} and Schuller, {David E.} and Ensley, {John F.}",

year = "2007",

month = apr,

doi = "10.1080/07357900701209061",

language = "English (US)",

volume = "25",

pages = "182--188",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)

T2 - A Southwest Oncology Group phase II study

AU - Samlowski, Wolfram E.

AU - Moon, James

AU - Kuebler, J. Philip

AU - Nichols, Craig R.

AU - Gandara, David R

AU - Ozer, Howard

AU - Williamson, Stephen K.

AU - Atkins, James N.

AU - Schuller, David E.

AU - Ensley, John F.

PY - 2007/4

Y1 - 2007/4

N2 - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

AB - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

KW - Carboplatin

KW - Chemotherapy

KW - Docetaxel

KW - Head and neck cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=34347270591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347270591&partnerID=8YFLogxK

U2 - 10.1080/07357900701209061

DO - 10.1080/07357900701209061

M3 - Article

C2 - 17530488

AN - SCOPUS:34347270591

VL - 25

SP - 182

EP - 188

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this